Cadrenal Therapeutics, Inc.(CVKD)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
CVKD Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Cadrenal Therapeutics, Inc. (CVKD), a Healthcare sector company. CVKD is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Cadrenal Therapeutics, Inc. reports net income of $-2.5M, free cash flow of $-3.0M. Top institutional holders of CVKD by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT,, VANGUARD FIDUCIARY CO, based on the most recent SEC filings. CVKD trades on the Nasdaq exchange and files with the SEC under CIK 1937993. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CVKD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cadrenal Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-2.5M
Free Cash Flow
Q1 2026
$-3.0M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
-58.4% YoYOperating Income
-76.4% YoYEPS (Diluted)
+28.5% YoYTotal Assets
-49.2% YoYOp. Cash Flow
-257.0% YoY| Metric | FY 2025 | FY 2023 |
|---|---|---|
| Net Income | $-13.2M -58.4% | $-8.4M |
| Operating Income | $-13.5M -76.4% | $-7.6M |
| EPS (Diluted) | $-6.64 +28.5% | $-9.29 |
| Total Assets | $4.3M -49.2% | $8.5M |
| Operating Cash Flow | $-12.6M -257.0% | $-3.5M |
AI Insight: CVKD Financial Trends
Cadrenal shows steady burn rate reduction with quarterly losses narrowing from $4M to $2M over the past year, though equity base has eroded to $2M.
• Net losses improved from $4M in Q4 2024 to $2M in Q1 2026, showing consistent burn rate reduction.
• Operating losses similarly narrowed from $4M to $3M over the same period.
• Total equity declined from $7M in Q4 2024 to $2M in Q1 2026 as losses consumed capital.
⚠ Equity base down to $2M suggests potential near-term financing needs given ongoing quarterly losses.
⚠ Operating cash flow remains volatile, ranging from $2M to $5M outflows with no clear trend.
AI Insight: CVKD Ratio Trends
No financial ratio data available for Cadrenal Therapeutics across all reported periods.
• Operating margin, profitability, and return metrics unavailable across nine quarters from Q2 2024 through Q1 2026.
⚠ Complete absence of ratio data suggests potential data reporting issues or early-stage company status.
Get alerted when CVKD's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Cadrenal Therapeutics, Inc. including:
Top Institutional Holders of CVKD
VANGUARD CAPITAL MANAGEMENT LLC
$231.4K45,201 shGEODE CAPITAL MANAGEMENT, LLC
$110.7K21,626 shVANGUARD FIDUCIARY TRUST CO
$42.6K8,311 shBlackRock, Inc.
$28.1K5,496 shTower Research Capital LLC (TRC)
$2.0K393 shOSAIC HOLDINGS, INC.
$1.5K300 shDestiny Wealth Partners, LLC
$1.0K200 shRockefeller Capital Management L.P.
$768.00150 shMORGAN STANLEY
$512.00100 shHARBOUR INVESTMENTS, INC.
$512.00100 sh
| Fund | Value | Shares |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $231.4K | 45,201 |
| GEODE CAPITAL MANAGEMENT, LLC | $110.7K | 21,626 |
| VANGUARD FIDUCIARY TRUST CO | $42.6K | 8,311 |
| BlackRock, Inc. | $28.1K | 5,496 |
| Tower Research Capital LLC (TRC) | $2.0K | 393 |
| OSAIC HOLDINGS, INC. | $1.5K | 300 |
| Destiny Wealth Partners, LLC | $1.0K | 200 |
| Rockefeller Capital Management L.P. | $768.00 | 150 |
| MORGAN STANLEY | $512.00 | 100 |
| HARBOUR INVESTMENTS, INC. | $512.00 | 100 |
More Healthcare Companies
View all Healthcare →Put CVKD on your watchlist
Track score changes the day Cadrenal Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CVKD a good stock to buy?
13F Pro's AI-powered analysis of Cadrenal Therapeutics, Inc. (CVKD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CVKD are available on the CVKD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own CVKD?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CVKD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cadrenal Therapeutics, Inc.'s investment landscape.